Your browser doesn't support javascript.
loading
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for µ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
Obeng, Samuel; Wilkerson, Jenny L; León, Francisco; Reeves, Morgan E; Restrepo, Luis F; Gamez-Jimenez, Lea R; Patel, Avi; Pennington, Anna E; Taylor, Victoria A; Ho, Nicholas P; Braun, Tobias; Fortner, John D; Crowley, Morgan L; Williamson, Morgan R; Pallares, Victoria L C; Mottinelli, Marco; Lopera-Londoño, Carolina; McCurdy, Christopher R; McMahon, Lance R; Hiranita, Takato.
Afiliação
  • Obeng S; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Wilkerson JL; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • León F; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Reeves ME; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Restrepo LF; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Gamez-Jimenez LR; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Patel A; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Pennington AE; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Taylor VA; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Ho NP; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Braun T; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Fortner JD; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Crowley ML; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Williamson MR; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Pallares VLC; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Mottinelli M; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Lopera-Londoño C; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • McCurdy CR; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • McMahon LR; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
  • Hiranita T; Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Inst
J Pharmacol Exp Ther ; 376(3): 410-427, 2021 03.
Article em En | MEDLINE | ID: mdl-33384303
ABSTRACT
Relationships between µ-opioid receptor (MOR) efficacy and effects of mitragynine and 7-hydroxymitragynine are not fully established. We assessed in vitro binding affinity and efficacy and discriminative stimulus effects together with antinociception in rats. The binding affinities of mitragynine and 7-hydroxymitragynine at MOR (Ki values 77.9 and 709 nM, respectively) were higher than their binding affinities at κ-opioid receptor (KOR) or δ-opioid receptor (DOR). [35S]guanosine 5'-O-[γ-thio]triphosphate stimulation at MOR demonstrated that mitragynine was an antagonist, whereas 7-hydroxymitragynine was a partial agonist (Emax = 41.3%). In separate groups of rats discriminating either morphine (3.2 mg/kg) or mitragynine (32 mg/kg), mitragynine produced a maximum of 72.3% morphine-lever responding, and morphine produced a maximum of 65.4% mitragynine-lever responding. Other MOR agonists produced high percentages of drug-lever responding in the morphine and mitragynine discrimination assays 7-hydroxymitragynine (99.7% and 98.1%, respectively), fentanyl (99.7% and 80.1%, respectively), buprenorphine (99.8% and 79.4%, respectively), and nalbuphine (99.4% and 98.3%, respectively). In the morphine and mitragynine discrimination assays, the KOR agonist U69,593 produced maximums of 72.3% and 22.3%, respectively, and the DOR agonist SNC 80 produced maximums of 34.3% and 23.0%, respectively. 7-Hydroxymitragynine produced antinociception; mitragynine did not. Naltrexone antagonized all of the effects of morphine and 7-hydroxymitragynine; naltrexone antagonized the discriminative stimulus effects of mitragynine but not its rate-decreasing effects. Mitragynine increased the potency of the morphine discrimination yet decreased morphine antinociception. Here we illustrate striking differences in MOR efficacy, with mitragynine having less than 7-hydroxymitragynine. SIGNIFICANCE STATEMENT At human µ-opioid receptor (MOR) in vitro, mitragynine has low affinity and is an antagonist, whereas 7-hydroxymitragynine has 9-fold higher affinity than mitragynine and is an MOR partial agonist. In rats, intraperitoneal mitragynine exhibits a complex pharmacology including MOR agonism; 7-hydroxymitragynine has higher MOR potency and efficacy than mitragynine. These results are consistent with 7-hydroxymitragynine being a highly selective MOR agonist and with mitragynine having a complex pharmacology that combines low efficacy MOR agonism with activity at nonopioid receptors.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comportamento Animal / Receptores Opioides mu / Alcaloides de Triptamina e Secologanina Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comportamento Animal / Receptores Opioides mu / Alcaloides de Triptamina e Secologanina Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article